经皮入路与切开入路在EVAR中临床结局的Meta分析与试验序贯分析
该系统评价纳入4项随机对照试验共368例患者和530个入路部位,比较经皮与切开入路行标准腹主动脉瘤腔内修复的临床结局。Meta分析显示两组在入路部位并发症、感染、出血、动脉损伤、闭塞、假性动脉瘤及围术期死亡率方面无差异,经皮组血清肿/淋巴漏更少且手术时间更短,但证据质量低或极低,试验序贯分析未达所需信息量。
要点
- 经皮与切开入路在EVAR的主要临床结局上无显著差异。
- 经皮组血清肿/淋巴漏发生率显著更低(0% vs 3%,OR 0.18)。
- 经皮组手术时间平均缩短11.53分钟,但证据质量低或极低。
核心结论
- 经皮EVAR对临床重要结局的影响证据很不确定。
研究设计与样本
- 系统评价与Meta分析,纳入4项随机对照试验,共368例患者和530个入路部位。
- 检索MEDLINE和Embase,使用NICE开发的HDAS界面。
- 采用Mantel-Haenszel或逆方差法计算合并效应量,并进行试验序贯分析。
- 使用Cochrane修订版工具评估偏倚风险,GRADE系统分级证据质量。
主要发现
- 经皮与切开入路在入路部位并发症或感染、术后出血/血肿、入路相关动脉损伤、股动脉闭塞、假性动脉瘤或围术期死亡率方面无差异。
- 血清肿/淋巴漏在经皮EVAR后显著更少(0% vs 3%;OR 0.18,95%CI 0.04-0.83)。
- 经皮EVAR手术时间显著更短(MD -11.53分钟;95%CI -15.71至-7.34)。
- 两组住院时间无差异。
- 累积Z曲线未跨越O'Brien-Fleming界值或无效界值,任何结局均未达到所需信息量。
关键数值与推荐
- 血清肿/淋巴漏:经皮0% vs 切开3%,OR 0.18(95%CI 0.04-0.83)。
- 手术时间:MD -11.53分钟(95%CI -15.71至-7.34)。
- 所有试验存在高偏倚风险或一些问题,所有结局证据质量低或极低。
临床怎么用
- 经皮入路可作为EVAR的合理选择,尤其可能减少血清肿/淋巴漏并缩短手术时间。
- 临床决策应结合患者个体情况和术者经验,因证据质量低。
局限性
- 仅纳入4项随机对照试验,样本量有限。
- 所有试验存在高偏倚风险或一些问题,证据质量低或极低。
- 试验序贯分析未达到所需信息量,结果可能不精确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate whether a percutaneous approach has better clinical outcomes than surgical access for standard endovascular repair of abdominal aortic aneurysms. DATA SOURCES: MEDLINE and Embase were searched using the Healthcare Databases Advanced Search interface developed by the National Institute for Health and Care Excellence. REVIEW METHODS: Randomised controlled trials (RCTs) that compared percutaneous and cutdown endovascular aneurysm repair (EVAR) were considered. Pooled effect estimates were calculated using the odds ratio (OR), risk difference, or mean difference (MD) and 95% confidence interval (CI). The Mantel-Haenszel or inverse variance statistical method was used as appropriate. Trial sequential analysis was performed to quantify the available evidence and control for the risk of type 1 and type 2 error. Risk of bias was assessed with the revised tool developed by Cochrane and the quality of evidence was graded using the GRADE system (Grades of Recommendation, Assessment, Development and Evaluation). RESULTS: Four RCTs were identified, reporting a total of 368 patients and 530 access sites. Meta-analysis showed no difference in access site complications or infection, post-operative bleeding/haematoma, access related arterial injury, femoral artery occlusion, pseudo-aneurysm, or peri-operative mortality between percutaneous and cutdown EVAR. Seroma/lymphorrhoea was significantly less frequent after percutaneous EVAR (0%) compared with cutdown EVAR (3%; OR 0.18 [95% CI 0.04-0.83]) and the procedure time was significantly shorter (MD -11.53 minutes; 95% CI -15.71-7.34), but hospital length of stay was not different between treatments. Neither the O'Brien-Fleming boundaries nor the futility boundaries were crossed by the cumulative Z curve, and the required information size was not reached for any of the outcomes. All trials were judged to be high risk of bias or have some concerns, and the level of the body of evidence was low or very low for all outcomes. CONCLUSION: The evidence is very uncertain about the effect of percutaneous EVAR on clinically important outcomes.
引用
- Antoniou GA, Antoniou SA. Editor's Choice - Percutaneous Access Does Not Confer Superior Clinical Outcomes Over Cutdown Access for Endovascular Aneurysm Repair: Meta-Analysis and Trial Sequential Analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2020. PMID: 33309488. doi:10.1016/j.ejvs.2020.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。